Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:lumasiran
|
| gptkbp:approvalYear |
2020
|
| gptkbp:ATCCode |
M09AX10
|
| gptkbp:developer |
gptkb:Alnylam_Pharmaceuticals
|
| gptkbp:form |
solution for injection
|
| https://www.w3.org/2000/01/rdf-schema#label |
Oxlumo
|
| gptkbp:indication |
gptkb:primary_hyperoxaluria_type_1
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketingAuthorizationHolder |
gptkb:Alnylam_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
gptkb:RNA_interference
|
| gptkbp:pregnancyCategory |
not assigned
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:status |
FDA approved
EMA approved |
| gptkbp:target |
gptkb:hydroxyacid_oxidase_1_(HAO1)_mRNA
|
| gptkbp:bfsParent |
gptkb:Alnylam_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|